Last updated: February 25, 2026
What is the Drug with NDC 68094-0750?
The National Drug Code (NDC) 68094-0750 corresponds to Voretigene Neparvovec-rzyl (Luxturna). This gene therapy targets inherited retinal dystrophies caused by RPE65 gene mutations.
Market Overview
Indications and Patient Population
Luxturna is approved for patients with confirmed bi-allelic RPE65 mutation-associated retinal dystrophy. Estimates indicate approximately 1,000–2,000 eligible patients in the U.S. (per FDA approval reports), with similar figures in Europe and other markets.
Current Market Size
| Region |
Estimated Patients |
Prevalence Estimate (%) |
Market Penetration |
Potential Revenue (USD) |
| United States |
1,000–2,000 |
0.0003–0.0006 |
20–50% |
$100–$200 million |
| Europe |
800–1,600 |
0.0002–0.0004 |
10–40% |
$80–$160 million |
| Rest of World |
200–400 |
0.0001–0.0002 |
Low |
$20–$40 million |
Competitive Landscape
- Gene Therapy Market: Rapidly evolving, with several pipelines targeting inherited retinal diseases.
- Existing Treatments: No approved drug alternatives; supportive therapies predominate.
- Market Entry Barriers: High manufacturing costs, infrastructure for gene delivery, and payer coverage.
Pricing Analysis
Current List Price
Luxturna has an initial U.S. list price of approximately $425,000 per eye, totaling $850,000 for bilateral treatment per patient. European prices range around €450,000.
Pricing Model and Budget Impact
| Price Component |
Details |
| List price per treatment |
$425,000 per eye (bilateral: $850,000) |
| Reimbursement rate |
Usually 70–100%, varies by payer |
| Cost per patient |
Approx. $850,000 |
Cost-Effectiveness
Studies cite the therapy’s potential to reduce long-term care costs related to visual impairment, though high upfront costs pose reimbursement challenges.
Price Projection Outlook
Short-term (Next 1–2 Years)
Price will remain stable at current levels; demand limited by the small eligible population. Payer negotiations could influence final reimbursement figures.
Medium-term (3–5 Years)
- Increased competition from emerging gene therapies or alternative treatments could pressure prices downward.
- Cost reductions in manufacturing and public health negotiations may decrease overall treatment costs by 10–20%.
Long-term (Beyond 5 Years)
- Introduction of biosimilars or generics is unlikely due to gene therapy’s complexity and regulatory barriers.
- Reimbursement models may evolve toward value-based arrangements, tying payment to outcomes, potentially reducing upfront costs.
Market Drivers and Risks
Drivers
- Unmet medical need for rare inherited retinal disorders.
- Favorable regulatory landscape: FDA approval granted via accelerated pathways.
- Positive clinical outcomes: sustained visual function improvements reported.
Risks
- Manufacturing scale-up complexities increase costs.
- Payer resistance to high-cost therapies.
- Limited patient access due to diagnostic challenges and awareness.
Regulatory and Policy Factors
- FDA approval on December 19, 2017, with orphan drug designation.
- European Medicines Agency (EMA) approval in 2018.
- Payer negotiations increasingly focus on outcomes-based agreements.
Key Takeaways
- The NDC 68094-0750 corresponds to Luxturna, a gene therapy targeting RPE65-related retinal dystrophies.
- The current market value exceeds $850,000 per treatment, with limited patient access due to small eligible populations.
- Price stability is expected short-term; slight reductions anticipated as the market matures and manufacturing costs decline.
- Demand is constrained by the rarity of the condition but driven by high unmet needs and positive clinical outcomes.
- Competitive pressures are limited in the short term due to the therapy’s unique FDA approval, but future pipeline entrants could influence pricing.
FAQs
1. What rights and restrictions are associated with NDC 68094-0750?
Market authorization allows for reimbursement and distribution in specified regions. Off-label use is restricted unless supported by additional regulatory approval.
2. How are pricing negotiations typically conducted?
Pharmaceutical companies negotiate with payers through value-based agreements, often linking reimbursement to patient outcomes and cost offsets.
3. What future pricing trends are forecasted?
Pricing is expected to remain stable for the near term, with potential decreases driven by manufacturing efficiencies and emerging competitors.
4. How does the small patient population impact pricing strategies?
Rarity restricts volume but enables premium pricing. Companies often rely on high per-treatment prices to recover R&D and manufacturing investments.
5. What are the barriers to expanding access?
High costs, complex administration, diagnostic testing requirements, and limited provider familiarity hinder broader adoption.
References
[1] U.S. Food and Drug Administration (FDA). (2017). FDA approves novel gene therapy to treat patients with a rare form of inherited blindness.
[2] European Medicines Agency (EMA). (2018). Luxturna approval details.
[3] Kual et al. (2022). Market considerations for gene therapies in rare eye diseases. Journal of Medical Economics, 25(3), 312–319.
